These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23917533)

  • 1. Living donor and recipient screening for latent tuberculosis infection by tuberculin skin test and interferon-gamma releasing assay in a country with an intermediate burden of tuberculosis.
    Moon SM; Park IA; Kim SM; Park SJ; Jung JH; Kim YH; Park JB; Hong B; Lee SO; Choi SH; Kim YS; Woo JH; Park SK; Lee SK; Park JS; Han DJ; Kim SH
    J Infect Chemother; 2013 Oct; 19(5):1009-13. PubMed ID: 23917533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor predictability of QuantiFERON-TB assay in recipients and donors for tuberculosis development after kidney transplantation in an intermediate-TB-burden country.
    Jambaldorj E; Han M; Jeong JC; Koo TY; Min SI; Song EY; Ha J; Ahn C; Yang J
    BMC Nephrol; 2017 Mar; 18(1):88. PubMed ID: 28292277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic potential of interferon-gamma release assay to detect latent tuberculosis infection in kidney transplant recipients.
    Edathodu J; Varghese B; Alrajhi AA; Shoukri M; Nazmi A; Elgamal H; Aleid H; Alrabiah F; Ashraff A; Mahmoud I; Al-Hajoj S
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28170135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation.
    Kim SH; Lee SO; Park IA; Park SJ; Choi SH; Kim YS; Woo JH; Park SK; Park JS; Kim SC; Han DJ
    Transpl Infect Dis; 2010 Apr; 12(2):113-9. PubMed ID: 20113458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tests for latent tuberculosis in people with ESRD: a systematic review.
    Rogerson TE; Chen S; Kok J; Hayen A; Craig JC; Sud K; Kable K; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):33-43. PubMed ID: 23068425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.
    Girlanda S; Mantegani P; Baldissera E; Aiello P; Ratti M; Sabbadini MG; Fortis C
    Clin Rheumatol; 2010 Oct; 29(10):1135-41. PubMed ID: 20645117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country.
    Lin WC; Lin HH; Lee SS; Sy CL; Wu KS; Chen JK; Tsai HC; Chen YS
    J Microbiol Immunol Infect; 2016 Oct; 49(5):729-736. PubMed ID: 25442858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
    Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
    Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA.
    Cho H; Kim YW; Suh CH; Jung JY; Um YJ; Jung JH; Kim HA
    Lupus; 2016 Oct; 25(12):1341-8. PubMed ID: 26985011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.
    Sester M; van Leth F; Bruchfeld J; Bumbacea D; Cirillo DM; Dilektasli AG; Domínguez J; Duarte R; Ernst M; Eyuboglu FO; Gerogianni I; Girardi E; Goletti D; Janssens JP; Julander I; Lange B; Latorre I; Losi M; Markova R; Matteelli A; Milburn H; Ravn P; Scholman T; Soccal PM; Straub M; Wagner D; Wolf T; Yalcin A; Lange C;
    Am J Respir Crit Care Med; 2014 Nov; 190(10):1168-76. PubMed ID: 25303140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of latent tuberculosis by ELISPOT assay and tuberculin skin test.
    Du F; Zhang Z; Gao T; Liu Z; Jia H; Xing A; Du B; Sun Q; Cao T; Zhang Z
    Med Mal Infect; 2016 May; 46(3):150-3. PubMed ID: 27021933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis.
    Santos JA; Duarte R; Nunes C
    Pulmonology; 2020; 26(6):353-362. PubMed ID: 31843341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis infection in South Korean healthcare workers using a tuberculin skin test and whole blood interferon-gamma assay.
    Jong Lee K; Ae Kang Y; Mi Kim Y; Cho SN; Wook Moon J; Suk Park M; Kyu Kim S; Chang J; Sam Kim Y
    Scand J Infect Dis; 2010 Sep; 42(9):672-8. PubMed ID: 20482459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of latent tuberculosis infection in bacille Calmette-Guérin vaccinated subjects in China by interferon-gamma ELISpot assay.
    Zhang M; Wang H; Liao M; Chen X; Graner M; Zhu X; Zhang J; Yang Q; Lu H; Zhou B; Chen X
    Int J Tuberc Lung Dis; 2010 Dec; 14(12):1556-63. PubMed ID: 21144240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.